Last reviewed · How we verify
Cabergoline tablets
Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.
Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma).
At a glance
| Generic name | Cabergoline tablets |
|---|---|
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | Dopamine D2 receptor agonist |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Cabergoline binds to dopamine D2 receptors on lactotroph cells in the pituitary, mimicking dopamine's natural inhibitory effect on prolactin release. This leads to sustained suppression of elevated prolactin levels. It is used to treat hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas).
Approved indications
- Hyperprolactinemia
- Prolactin-secreting pituitary adenoma (prolactinoma)
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Abdominal pain
- Orthostatic hypotension
Key clinical trials
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms (PHASE2)
- Carbergoline for Antipsychotic Induced Hyperprolactinemia. (PHASE4)
- Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS (NA)
- Cabergoline for Episodic Migraine (PHASE2)
- A Study on Bioequivalence of Cabergoline Tablets in Human Body (PHASE1)
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment (PHASE4)
- Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabergoline tablets CI brief — competitive landscape report
- Cabergoline tablets updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI